The group conducted #proteomic and #phosphoproteomic analyses to track how EGFR-mutant #LungCancer cells respond to Osimertinib treatment over time, mapping how cells transition into drug-tolerant cells.
0
0
1
0
The group conducted #proteomic and #phosphoproteomic analyses to track how EGFR-mutant #LungCancer cells respond to Osimertinib treatment over time, mapping how cells transition into drug-tolerant cells.
π§ͺ Our #phosphoproteomic data reveal that low vs. high doses of D1 agonist trigger completely different signaling profiles.
Itβs as if we were administering two entirely different drugs β astonishing!
Embarrassingly, an answer was sitting in a Supplemental data file published 7 YEARS EARLIER by #phosphoproteomic experts π³ π€¦: 4/10 www.pnas.org/doi/full/10....